ABUS)首席执行官马克•默里(Mark Murray)在2018年第二季度财报电

newchinabok

https://seekingalpha.com/article ... ngs-call-transcript

newchinabok

Arbutus Biopharma Corp (ABUS) CEO Mark Murray on Q2 2018 Results - Earnings Call Transcript

Aug. 3, 2018 12:32 AM ET  | About: Arbutus Biopharma Corp (ABUS)
Q2: 07-26-18 Earnings Summary
Press Release  News
EPS of $-0.44 Revenue of $1.2M (+ 20.0% Y/Y)
Arbutus Biopharma Corp (NASDAQ:ABUS) Q2 2018 Earnings Conference Call August 2, 2018 4:30 PM ET

Executives

Pam Murphy - IR

Mark Murray - CEO

Michael Sofia - CSO

William Symonds - Chief Development Officer

David Hastings - CFO

Koert VandenEnden - Chief Accounting Officer

Analysts

Liisa Bayko - JMP Securities

Katherine Xu - William Blair

Keay Nakae - Chardan

Madhu Kumar - B. Riley FBR

Operator

Good afternoon, ladies and gentlemen, and welcome to the Arbutus Biopharma Second Quarter 2018 Financial Results and Corporate Update Conference Call. [Operator Instructions] As a reminder this conference call is being recorded.

I'll now turn the call over to Pam Murphy, who has recently joined the Arbutus team as their IR Consultant. You may begin.

Pam Murphy

Thank you, operator. And good afternoon everyone and thanks for joining us. With me today are Dr. Mark Murray, Arbutus' CEO; Dr. Mike Sofia, Arbutus' Chief Scientific Officer; Dr. Bill Symonds, Arbutus' Chief Development Officer; Dave. Hastings, Arbutus' Chief Financial Officer; and, Koert VandenEnden, Arbutus' Chief Accounting Officer.

Before we begin, let me remind you that some of the statements made during the call today, are forward-looking statements including statements regarding developing accure for chronic HBV, the clinical development plan and potential for AB-506 and AB-452, Genevant development of delivery technologies and the potential of a development partnership, our clinical plan for ARB-1467 along with potential efficacy and timing of reported results, our expected cash runway, timing of regulatory filings and approval and expected revenues from our current and potential licensing agreements.

All of these statements involve certain assumptions, risks and uncertainties that are beyond our control and can cause our actual results to differ materially. A description of these risks can be found in our latest disclosure documents and current press releases. In addition, Arbutus does not undertake any obligation to update any forward-looking statements made during this call.

I'd now like to pass the call to Mark for his introductory remarks.

Mark Murray

Thanks, Pam. And thank you to everyone for joining us on the call today. Our mission is to develop a cure for chronic hepatitis B using a combination of orally active therapeutic agents, which is effective in the defined treatment duration. To that end, we have developed a pipeline of proprietary therapeutic agents that target multiple agents of the HPV lifecycle, the most important of which are HPV data replication and HPV surface antigen expression.

Last month, we initiated our Phase 1A/1B clinical trial of AB-506 our second generation capsid inhibitor agent. We will shortly file our regulatory submission to start the Phase 1A/1B clinical study of our RNA destabilizer agent AB-452. We expect patient monotherapy results from both of these studies by mid-2019 and we expect to combine these in the first ever oral combination study by the end of 2019.

In addition during the first half of the year we completed a number of strategic initiatives to keep our team, our business activities and our capital resources more closely focused on HPV. We have successfully completed a site consolidation that concentrates our business activities in a single location in Warminster, Pennsylvania. We have successfully launched Genevant Sciences together with Roivant.

Genevant is wholly focused on utilizing Arbutus's proprietary LNP and ligand conjugate delivery technologies to develop RNA-based therapies and we've retained a substantial equity interest in Genevant as well as the potential for future royalties on commercialized products. We're encouraged by Genevant's recently announced partnership with BioNTech for the co-development of five mRNA products which we see as being potentially a transformative partnership in the field combining an industry leading mRNA portfolio with the industry leading delivery technologies of Genevant.

newchinabok

Arbutus Biopharma Corp (ABUS)首席执行官马克•默里(Mark Murray)在2018年第二季度财报电话会议上的发言
女士们、先生们，下午好，欢迎大家来到2018年第二季度的Arbutus Biopharma财务报告和企业更新电话会议。【操作人员说明】作为提醒，本次电话会议正在录音。
我现在把电话转给帕姆·墨菲(Pam Murphy)，她最近作为他们的IR顾问加入了Arbutus团队。你可能开始。
Pam墨菲
谢谢你,运营商。大家下午好，谢谢大家。今天和我一起的是Mark Murray博士，Arbutus的首席执行官;麦克·索非亚博士，阿布图斯的首席科学官;比尔·西蒙兹博士，奥布斯的首席发展官;戴夫。哈斯廷斯，阿布图斯的首席财务官;阿布图斯的首席会计官柯尔特·范登登登(Koert VandenEnden)表示。
在我们开始之前,让我提醒你,在今天的一些陈述,前瞻性陈述包括声明关于发展为慢性乙肝病毒遭受沙尘暴,临床潜力发展规划和ab - 506和ab - 452,交货Genevant开发技术和开发伙伴关系的潜力,我们的临床计划arb - 1467报告结果的潜在功效和时机,我们预期现金跑道,监管申报和批准的时间，以及我们当前和潜在许可协议的预期收入。
所有这些陈述都涉及某些假设、风险和不确定性，这些都超出了我们的控制范围，并可能导致我们的实际结果出现实质性差异。这些风险的描述可以在我们的最新披露文件和当前的新闻稿中找到。此外，Arbutus不承担任何义务更新在这次电话会议期间所作的任何前瞻性声明。
我现在想把马克的介绍性发言的电话转给他。
马克·莫里
谢谢,Pam。感谢大家今天参加我们的电话会议。我们的任务是开发一种治疗慢性乙型肝炎的药物联合口服活性治疗药物，这在确定的治疗时间是有效的。为此，我们开发了一系列针对多种HPV生命周期介质的专用治疗药物，其中最重要的是HPV数据复制和HPV表面抗原表达。
上个月，我们开始了第二代衣壳抑制剂AB-506的1A/1B期临床试验。我们将很快提交我们的监管文件，开始我们的RNA不稳定剂AB-452的1A/1B期临床研究。我们预计患者的单药治疗效果将在2019年年中完成，我们预计在2019年底前首次口服联合治疗中合并这两项研究。
此外，在今年上半年，我们完成了多项战略计划，以使我们的团队、商业活动和资本资源更加专注于HPV。我们已经成功地完成了在宾夕法尼亚州沃明斯特的一个单一地点集中我们的业务活动的地点合并。我们与罗凡特一起成功地启动了Genevant科学。
Genevant完全专注于利用Arbutus的专有LNP和配体结合技术来开发基于rna的治疗方法，我们保留了Genevant的大量股权，以及未来商业化产品的专利权使用费。Genevant最近宣布与BioNTech合作，共同开发5种mRNA产品，我们对此感到鼓舞。我们认为，这是该领域潜在的转型合作伙伴关系，将行业领先的mRNA组合与Genevant行业领先的交付技术结合起来。